Retatrutide
GLP-1 / GIP / Glucagon Triple Receptor Agonist
Retatrutide is a novel triple receptor agonist that simultaneously targets GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors. This multi-receptor engagement profile makes it a compelling subject for metabolic research, particularly in studies examining energy homeostasis, adipose tissue regulation, and glycemic control mechanisms. Research applications include in-vitro receptor binding assays, cellular signaling pathway studies, and preclinical metabolic models.
Product Specifications
Store lyophilized at -20°C. Reconstituted solution stable at 4°C for up to 7 days.
≥98% by HPLC
Lyophilized Powder
Research Notes
Mechanism of Action
Acts as a full agonist at GLP-1R, GIPR, and GcgR. The triple agonism profile is hypothesized to produce additive or synergistic effects on energy expenditure and substrate utilization compared to single or dual receptor agonists, making it a valuable research tool for dissecting incretin and glucagon biology.
Research Use Only. This product is intended solely for in-vitro research and laboratory use by qualified researchers. It is not approved for human or animal consumption, therapeutic use, or diagnostic application. By purchasing, you confirm compliance with all applicable laws and regulations.
Also Available